Marcia Belvin
CIK: 0001970752
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CytomX Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Mar 17, 2026CTMX
CytomX Therapeutics, Inc.
Sale(S)Direct31.5K shares at avg. $6.42$202K - Feb 2, 2026CTMX
CytomX Therapeutics, Inc.
Award(A)Direct60K shares- - Sep 26, 2025CTMX
CytomX Therapeutics, Inc.
Award(A)DirectPerformance Stock Units (PSUs)
18.2K shares- - Sep 26, 2025CTMX
CytomX Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
36.3K shares- - Jun 16, 2025CTMX
CytomX Therapeutics, Inc.
Sale(S)Direct13.9K shares at avg. $2.69$37K - Jun 13, 2025CTMX
CytomX Therapeutics, Inc.
Exercise(M)Direct37.5K shares- - Mar 18, 2025CTMX
CytomX Therapeutics, Inc.
Sale(S)Direct19.5K shares at avg. $0.60$12K - Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
Award(A)Direct57.5K shares- - Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
Award(A)Direct35K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 17, 2026 | CTMX CytomX Therapeutics, Inc. | Sale(S) | 31,492 | $6.42 | $202,273 | Direct |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | Award(A) | 60,000 | - | $0 | Direct |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | Award(A) Performance Stock Units (PSUs) | 18,150 | - | - | Direct |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 36,300 | - | - | Direct |
| Jun 16, 2025 | CTMX CytomX Therapeutics, Inc. | Sale(S) | 13,884 | $2.69 | $37,334 | Direct |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | Exercise(M) | 37,500 | - | - | Direct |
| Mar 18, 2025 | CTMX CytomX Therapeutics, Inc. | Sale(S) | 19,512 | $0.60 | $11,688 | Direct |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | Award(A) | 57,500 | - | - | Direct |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | Award(A) | 35,000 | - | - | Direct |
1-9 of 9 transactions
About BELVIN MARCIA
BELVIN MARCIA (SEC CIK 0001970752) files insider reports with the SEC as SVP, Chief Scientific Officer of CytomX Therapeutics, Inc. (CTMX).
Signal8 holds 7 ownership filings by BELVIN MARCIA, all Form 4s, filed between Feb 6, 2025 and Mar 19, 2026. Those filings report 9 transactions, from Feb 4, 2025 to Mar 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BELVIN MARCIA's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by BELVIN MARCIA
- Mar 17, 2026: Open-market sale of CTMX shares (Form 4, code S).
- Feb 2, 2026: Grant or award of CTMX shares (Form 4, code A).
- Sep 26, 2025: Grants or awards of CTMX derivative securities (2 lines, Form 4, code A).
- Jun 16, 2025: Open-market sale of CTMX shares (Form 4, code S).
- Jun 13, 2025: Option exercise of CTMX shares (Form 4, code M).
Other insiders filing for CytomX Therapeutics, Inc. (CTMX)
- McCarthy Sean A., CEO
- Carvajal Alejandra, Chief Legal Officer
- Fuchs Charles S., Director
- Su Zhen, Director
- Young Matthew P., Director
- Mohindru Mani, Director